The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy

References

• Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975;16:216–229. doi:10.1002/ijc.2910160204
   PubMed Web of Science ®Google Scholar
• Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18:671–688. doi:10.1038/s41577-018-0061-z
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Expanded and armed natural killer cells for cancer treatment. Cytotherapy. 2016;18(11):1422–1434. doi:10.1016/j.jcyt.2016.06.013
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–469. doi:10.1182/blood-2007-09-077438
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932–5943. doi:10.1038/onc.2008.267
   PubMed Web of Science ®Google Scholar
• Carlsten M, Malmberg KJ, Ljunggren HG. Natural killer cell-mediated lysis of freshly isolated human tumor cells. Int J Cancer. 2009;124(4):757–762. doi:10.1002/ijc.24082
   Web of Science ®Google Scholar
• Li L, Li W, Wang C, et al. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma. Cytotherapy. 2018;20(1):134–148. doi:10.1016/j.jcyt.2017.09.009
   Web of Science ®Google Scholar
• Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989;169:2233–2238. doi:10.1084/jem.169.6.2233
   PubMed Web of Science ®Google Scholar
• Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol. 2013;34(12):573–582. doi:10.1016/j.it.2013.07.005
   Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010–4017. doi:10.1158/0008-5472.CAN-08-3712
   PubMed Web of Science ®Google Scholar
• Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol. 2009;9(8):568–580. doi:10.1038/nri2604
   PubMed Web of Science ®Google Scholar
• Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–465. doi:10.1111/j.1365-2567.2008.03027.x
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Qin S, Unutmaz D, et al. Unique subpopulations of CD561 NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol. 2001;166(11):6477–6482. doi:10.4049/jimmunol.166.11.6477
   PubMed Web of Science ®Google Scholar
• Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47(5):820–833. doi:10.1016/j.immuni.2017.10.008
   PubMed Web of Science ®Google Scholar
• Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013;132(3):536–544. doi:10.1016/j.jaci.2013.07.006
   PubMed Web of Science ®Google Scholar
• Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675–678. doi:10.1038/319675a0
   PubMed Web of Science ®Google Scholar
• Kärre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol. 2002;55(3):221–228. doi:10.1046/j.1365-3083.2002.01053.x
   PubMed Web of Science ®Google Scholar
• Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 2014;122:91–128. doi:10.1016/B978-0-12-800267-4.00003-1
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19. doi:10.1038/nrc.2015.5
   PubMed Web of Science ®Google Scholar
• Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol. 2011;32(8):364–372. doi:10.1016/j.it.2011.06.001
   Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428):727–729. doi:10.1126/science.285.5428.727
   PubMed Web of Science ®Google Scholar
• Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28:4390–4399. doi:10.1200/JCO.2009.27.6360
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49. doi:10.1126/science.1198687
   PubMed Web of Science ®Google Scholar
• Deniz G, van de Veen W, Akdis M. Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol. 2013;132(3):527–535. doi:10.1016/j.jaci.2013.07.030
   PubMed Web of Science ®Google Scholar
• Ingram Z, Madan S, Merchant J, et al. Targeting natural killer T cells in solid malignancies. Cells. 2021;10(6):1329. doi:10.3390/cells10061329
   Web of Science ®Google Scholar
• Villegas FR, Coca S, Villarrubia VG, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35(1):23–28. doi:10.1016/s0169-5002(01)00292-6
   PubMed Web of Science ®Google Scholar
• Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2001;121(6):1058–1063. doi:10.1067/mtc.2001.113026
   Web of Science ®Google Scholar
• Putz EM, Mayfosh AJ, Kos K, et al. NK cell heparanase controls tumor invasion and immune surveillance. J Clin Invest. 2017;127(7):2777–2788. doi:10.1172/JCI92958
   PubMed Web of Science ®Google Scholar
• Malmberg KJ, Carlsten M, Björklund A, Sohlberg E, Bryceson YT, Ljunggren HG. Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017;31:20–29. doi:10.1016/j.smim.2017.08.002
   PubMed Web of Science ®Google Scholar
• López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135–154. doi:10.1016/j.ccell.2017.06.009
   PubMed Web of Science ®Google Scholar
• Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol. 2010;651:61–77. doi:10.1007/978-1-60761-786-0_4
   PubMedGoogle Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–1492. doi:10.1056/NEJM198512053132327
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Mechanisms of resistance to NK cell immunotherapy. Cancers. 2020;12(4):893. doi:10.3390/cancers12040893
   Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025–1036. doi:10.1038/ni.3518
   PubMed Web of Science ®Google Scholar
• Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol. 2013;78(2):120–129. doi:10.1111/sji.12072
   PubMed Web of Science ®Google Scholar
• Zingoni A, Vulpis E, Nardone I, et al. Targeting NKG2D and NKp30 ligands shedding to improve NK cell-based immunotherapy. Crit Rev Immunol. 2016;36(6):445–460. doi:10.1615/CritRevImmunol.2017020166
   Web of Science ®Google Scholar
• Cong J, Wei H. Natural killer cells in the lungs. Front Immunol. 2019;10:1416. doi:10.3389/fimmu.2019.01416
   PubMed Web of Science ®Google Scholar
• Marquardt N, Kekäläinen E, Chen P, et al. Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69−CD56dim cells. J Allergy Clin Immunol. 2017;139(4):1321–1330.e4. doi:10.1016/j.jaci.2016.07.043
   PubMed Web of Science ®Google Scholar
• Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology. 2009;128(2):151–163. doi:10.1111/j.1365-2567.2009.03167.x
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8:183–192. doi:10.1038/nri2254
   PubMed Web of Science ®Google Scholar
• Freeman CM, Stolberg VR, Crudgington S, et al. Human CD56+ cytotoxic lung lymphocytes kill autologous lung cells in chronic obstructive pulmonary disease. PLoS One. 2014;9(7):e103840. doi:10.1371/journal.pone.0103840
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376. doi:10.1016/S0065-2776(08)60664-1
   PubMed Web of Science ®Google Scholar
• Marquardt N, Beziat V, Nyström S, et al. Cutting edge: identification and characterization of human intrahepatic CD49a1 NK cells. J Immunol. 2015;194(6):2467–2471. doi:10.4049/jimmunol.1402756
   Web of Science ®Google Scholar
• Robinson BW, Pinkston P, Crystal RG. Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest. 1984;74:942–950. doi:10.1172/JCI111513
   PubMed Web of Science ®Google Scholar
• Cooper GE, Ostridge K, Khakoo SI, Wilkinson TMA, Staples KJ. Human CD49a+ lung natural killer cell cytotoxicity in response to influenza A virus. Front Immunol. 2018;9:1671. doi:10.3389/fimmu.2018.01671
   PubMed Web of Science ®Google Scholar
• Björkström N, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116(19):3853–3864. doi:10.1182/blood-2010-04-281675
   PubMed Web of Science ®Google Scholar
• Hervier B, Russick J, Cremer I, Vieillard V. NK cells in the human lungs. Front Immunol. 2019;10:1263. doi:10.3389/fimmu.2019.01263
   Web of Science ®Google Scholar
• Marquardt N, Kekäläinen E, Chen P, et al. Unique transcriptional and protein-expression signature in human lung tissue-resident NK cells. Nat Commun. 2019;10(1):3841. doi:10.1038/s41467-019-11632-9
   PubMed Web of Science ®Google Scholar
• Lopez-Verges S, Milush J, Pandey S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD161 NK-cell subset. Blood. 2010;116:3865–3874. doi:10.1182/blood-2010-04-282301
   PubMed Web of Science ®Google Scholar
• Sathaliyawala T, Kubota M, Yudanin N, et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity. 2013;38:187–197. doi:10.1016/j.immuni.2012.09.020
   PubMed Web of Science ®Google Scholar
• Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103(3):463–473. doi:10.1016/j.mcna.2018.12.006
   PubMed Web of Science ®Google Scholar
• Nguyen AH, Berim IG, Agrawal DK. Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol. 2014;10(12):1711–1730. doi:10.1586/1744666X.2014.975692
   PubMed Web of Science ®Google Scholar
• Aktaş ON, Öztürk AB, Erman B, Erus S, Tanju S, Dilege Ş. Role of natural killer cells in lung cancer. J Cancer Res Clin Oncol. 2018;144(6):997–1003. doi:10.1007/s00432-018-2635-3
   PubMed Web of Science ®Google Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412–5422. doi:10.1158/0008-5472.CAN-10-4179
   PubMed Web of Science ®Google Scholar
• Al Omar SY, Marshall E, Middleton D, Christmas SE. Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology. 2011;133(1):94–104. doi:10.1111/j.1365-2567.2011.03415.x
   Web of Science ®Google Scholar
• Yang L, Wang L, Zhang Y. Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol. 2016;5(1):1–20.
   PubMed Web of Science ®Google Scholar
• Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol. 2008;83(3):774–784. doi:10.1189/jlb.0707481
   Web of Science ®Google Scholar
• Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA. 2003;100(7):4120–4125. doi:10.1073/pnas.0730640100
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human non-small-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863–875. doi:10.1002/cncr.23239
   PubMed Web of Science ®Google Scholar
• Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169:750–765.e17. doi:10.1016/j.cell.2017.04.014
   PubMed Web of Science ®Google Scholar
• Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016;16(5):310–320. doi:10.1038/nri.2016.34
   PubMed Web of Science ®Google Scholar
• Hodge G, Barnawi J, Jurisevic C, et al. Lung cancer is associated with decreased expression of perforin, granzyme B and IFNγ by infiltrating lung tissue T cells, NKT-like and NK cells. Clin Exp Immunol. 2014;178(1):79–85. doi:10.1111/cei.12392
   Web of Science ®Google Scholar
• O’Brien KL, Finlay DK. Immunometabolism and natural killer cell responses. Nat Rev Immunol. 2019;19(5):282–290. doi:10.1038/s41577-019-0139-2
   PubMed Web of Science ®Google Scholar
• Cong J, Wang X, Zheng X, et al. Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metab. 2018;28(2):243–255.e5. doi:10.1016/j.cmet.2018.06.021
   PubMed Web of Science ®Google Scholar
• Bruno A, Focaccetti C, Pagani A, et al. The proangiogenic phenotype of natural killer cells in patients with non – small cell lung cancer. Neoplasia. 2013;15:133–142. doi:10.1593/neo.121758
   PubMed Web of Science ®Google Scholar
• Hamilton G, Rath B. Immunotherapy for small cell lung cancer: mechanisms of resistance. Expert Opin Biol Ther. 2019;19(5):423–432. doi:10.1080/14712598.2019.1592155
   PubMed Web of Science ®Google Scholar
• Zhu M, Huang Y, Bender ME, et al. Evasion of innate immunity contributes to small cell lung cancer progression and metastasis. Cancer Res. 2021;81(7):1813–1826. doi:10.1158/0008-5472.can-20-2808
   Web of Science ®Google Scholar
• Regzedmaa O, Zhang H, Liu H, Chen J. Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges. Onco Targets Ther. 2019;12:4605–4620. doi:10.2147/OTT.S204577
   PubMed Web of Science ®Google Scholar
• Pakkala S, Owonikoko TK. Immune checkpoint inhibitors in small cell lung cancer. J Thorac Dis. 2018;10(Suppl 3):S460–S467. doi:10.21037/jtd.2017.12.51
   PubMed Web of Science ®Google Scholar
• Vivier E, Ugolini S. Natural killer cells: from basic research to treatments. Front Immunol. 2011;2:18. doi:10.3389/fimmu.2011.00018
   PubMed Web of Science ®Google Scholar
• Doyle A, Martin WJ, Funa K, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985;161(5):1135–1151. doi:10.1084/jem.161.5.1135
   PubMed Web of Science ®Google Scholar
• Busch S, Hanke M, Kargl J, Metz H, MacPherson D, Houghton A. Lung cancer subtypes generate unique immune responses. J Immunol. 2016;197(11):4493–4503. doi:10.4049/jimmunol.1600576
   PubMed Web of Science ®Google Scholar
• Hofman P. New insights into the interaction of the immune system with non-small cell lung carcinomas. Transl Lung Cancer Res. 2020;9(5):2199–2213. doi:10.21037/tlcr-20-178
   PubMed Web of Science ®Google Scholar
• Schmidt L, Eskiocak B, Kohn R, et al. Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. Proc Natl Acad Sci USA. 2019;116:17460–17469. doi:10.1073/pnas.1904253116
   Web of Science ®Google Scholar
• Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol. 2011;11(10):645–657. doi:10.1038/nri3044
   PubMed Web of Science ®Google Scholar
• Sek K, Mølck C, Stewart GD, et al. Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci. 2018;19:3837. doi:10.3390/ijms19123837
   PubMed Web of Science ®Google Scholar
• Inoue Y, Yoshimura K, Kurabe N, et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget. 2017;8:8738–8751. doi:10.18632/oncotarget.14434
   PubMedGoogle Scholar
• Mediavilla-Varela M, Castro J, Chiappori A, et al. A novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment. Neoplasia. 2017;19:530–536. doi:10.1016/j.neo.2017.02.004
   PubMed Web of Science ®Google Scholar
• Vigano S, Alatzoglou D, Irving M, et al. Targeting adenosine in cancer immunotherapy to enhance T-cell function. Front Immunol. 2019;10:925. doi:10.3389/fimmu.2019.00925
   PubMed Web of Science ®Google Scholar
• Heeke S, Mograbi B, Alix-Panabières C, et al. Never travel alone: the crosstalk of circulating tumor cells and the blood microenvironment. Cells. 2019;8(7):714. doi:10.3390/cells8070714
   Web of Science ®Google Scholar
• Wang WC, Zhang XF, Peng J, et al. Survival mechanisms and influence factors of circulating tumor cells. BiomedRes Int. 2018;2018:6304701. doi:10.1155/2018/6304701
   PubMed Web of Science ®Google Scholar
• De Vito C, Mikulak J, Zaghi E, et al. NK cells to cure cancer. Semin Immunol. 2019;41:101272. doi:10.1016/j.smim.2019.03.004
   Web of Science ®Google Scholar
• Russick J, Joubert PE, Gillard-Bocquet M, et al. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. J Immunother Cancer. 2020;8(2):e001054. doi:10.1136/jitc-2020-001054
   PubMed Web of Science ®Google Scholar
• Kuppen PJ, Van Der Eb MM, Jonges LE, et al. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem Cell Biol. 2001;115(1):67–72. doi:10.1007/s004180000224
   Web of Science ®Google Scholar
• Clift R, Souratha J, Garrovillo SA, Zimmerman S, Blouw B. Remodeling the tumor microenvironment sensitizes breast tumors to anti-programmed death-ligand 1 immunotherapy. Cancer Res. 2019;79(16):4149–4159. doi:10.1158/0008-5472.CAN-18-3060
   Web of Science ®Google Scholar
• Jin S, Deng Y, Hao JW, et al. NK cell phenotypic modulation in lung cancer environment. PLoS One. 2014;9(10):e109976. doi:10.1371/journal.pone.0109976
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of Anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Sun H, Sun C. The rise of NK cell checkpoints as promising therapeutic targets in cancer immunotherapy. Front Immunol. 2019;10:2354. doi:10.3389/fimmu.2019.02354
   PubMed Web of Science ®Google Scholar
• Luna JI, Grossenbacher SK, Murphy WJ, Canter RJ. Targeting cancer stem cells with natural killer cell immunotherapy. Expert Opin Biol Ther. 2017;17(3):313–324. doi:10.1080/14712598.2017.1271874
   PubMed Web of Science ®Google Scholar
• Kim S, Iizuka K, Aguila HL, et al. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA. 2000;97(6):2731–2736. doi:10.1073/pnas.050588297
   Web of Science ®Google Scholar
• Zhang G, Zhao H, Wu J, et al. Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. Int Immunopharmacol. 2014;21(2):396–405. doi:10.1016/j.intimp.2014.04.026
   Web of Science ®Google Scholar
• Lin M, Liang SZ, Wang XH, et al. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res. 2017;65(4):880–887. doi:10.1007/s12026-017-8927-x
   PubMed Web of Science ®Google Scholar
• Ding X, Cao H, Chen X, et al. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Transl Med. 2015;13:158. doi:10.1186/s12967-015-0514-0
   PubMed Web of Science ®Google Scholar
• Romagnani C, Juelke K, Falco M, et al. CD56bright CD162 KIR2 NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007;178:4947–4955. doi:10.4049/jimmunol.178.8.4947
   PubMed Web of Science ®Google Scholar
• Esendagli G, Bruderek K, Goldmann T, et al. Malignant and nonmalignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer. 2008;59(1):32–40. doi:10.1016/j.lungcan.2007.07.022
   Web of Science ®Google Scholar
• Hiraki A, Kiura K, Yamane H, et al. Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer. 2002;35:329–333. doi:10.1016/s0169-5002(01)00424-x
   PubMed Web of Science ®Google Scholar
• Krause SW, Gastpar R, Andreesen R, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res. 2004;10:3699–3707. doi:10.1158/1078-0432.CCR-03-0683
   PubMed Web of Science ®Google Scholar
• Brownlie D, Scharenberg M, Mold J, et al. Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood. Proc Natl Acad Sci U S A. 2021;118(11):e2016580118. doi:10.1073/pnas.2016580118
   Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016;16(2):112–123. doi:10.1038/nri.2015.9
   PubMed Web of Science ®Google Scholar
• Chen Z, Yang Y, Liu LL, Lundqvist A. Strategies to augment natural killer (NK) cell activity against solid tumors. Cancers. 2019;11(7):1040. doi:10.3390/cancers11071040
   Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M. SEER Cancer Statistic Review. Bethesda, MD: National Cancer Institute; 2019.
   Google Scholar
• Poznanski SM, Ritchie TM, Fan IY, et al. Expanded human NK cells from lung cancer patients sensitize patients’ PDL1-negative tumors to PD1-blockade therapy. J Immunother Cancer. 2021;9(1):e001933. doi:10.1136/jitc-2020-001933
   Web of Science ®Google Scholar
• Yu Y, Zeng D, Ou Q, et al. Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis. JAMA Netw Open. 2019;2(7):e196879. doi:10.1001/jamanetworkopen.2019.6879
   PubMed Web of Science ®Google Scholar
• Chen S, Crabill GA, Pritchard TS, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305. doi:10.1186/s40425-019-0770-2
   PubMed Web of Science ®Google Scholar
• Chang CH, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229–1241. doi:10.1016/j.cell.2015.08.016
   PubMed Web of Science ®Google Scholar
• Lin M, Luo H, Liang S, et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest. 2020;130:2560–2569. doi:10.1172/JCI132712
   Web of Science ®Google Scholar
• Barkholt L, Alici E, Conrad R, et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 2009;1(5):753–764. doi:10.2217/imt.09.47
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287–6297. doi:10.1158/1078-0432.CCR-11-1347
   PubMed Web of Science ®Google Scholar
• Mantovani S, Oliviero B, Varchetta S, Mele D, Mondelli MU. Natural killer cell responses in hepatocellular carcinoma: implications for novel immunotherapeutic approaches. Cancers. 2020;12(4):926. doi:10.3390/cancers12040926
   Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100. doi:10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Kang S, Gao X, Zhang L, Yang E, Li Y, Yu L. The advances and challenges of NK cell-based cancer immunotherapy. Curr Oncol. 2021;28(2):1077–1093. doi:10.3390/curroncol28020105
   Web of Science ®Google Scholar
• Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol. 2015;6:195. doi:10.3389/fimmu.2015.00195
   PubMed Web of Science ®Google Scholar
• Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85–100. doi:10.1038/s41571-020-0426-7
   PubMed Web of Science ®Google Scholar
• Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652–658.
   PubMed Web of Science ®Google Scholar
• Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91. doi:10.3389/fimmu.2016.00091
   PubMed Web of Science ®Google Scholar
• Williams BA, Law AD, Routy B, et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017;8(51):89256–89268. doi:10.18632/oncotarget.19204
   PubMedGoogle Scholar
• Suck G, Odendahl M, Nowakowska P, et al. NK-92: an ‘off- the-shelf therapeutic’-for adoptive natural killer cell- based cancer-immunotherapy. Cancer Immunol Immunother. 2016;65(4):485–492. doi:10.1007/s00262-015-1761-x
   PubMed Web of Science ®Google Scholar
• Tonn T, Schwabe D, Klingemann HG, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15(12):1563–1570. doi:10.1016/j.jcyt.2013.06.017
   PubMed Web of Science ®Google Scholar
• Jochems C, Hodge JW, Fantini M, et al. An NK cell line (haNK) expressing-high levels of granzyme and engineered to express the-high affinity CD16 allele. Oncotarget. 2016;7:86359–86373. doi:10.18632/oncotarget.13411
   PubMedGoogle Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47. doi:10.1038/nri2206
   PubMed Web of Science ®Google Scholar
• Pahl JHW, Koch J, Götz JJ, et al. CD16A activation of NK cells promotes NK cell proliferation and memory-like cytotoxicity against cancer cells. Cancer Immunol Res. 2018;6(5):517–527. doi:10.1158/2326-6066.CIR-17-0550
   PubMed Web of Science ®Google Scholar
• Kendra K, Malkovska V, Allen M, Guzman J, Albertini M. In vivo binding and antitumor activity of Ch14.18. J Immunother. 1999;22(5):423–430. doi:10.1097/00002371-199909000-00006
   Web of Science ®Google Scholar
• Benson DM, Hofmeister CC, Padmanabhan S, et al. A Phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012;120(22):4324–4433. doi:10.1182/blood-2012-06-438028
   PubMed Web of Science ®Google Scholar
• Spanholtz J, Preijers F, Tordoir M, et al. Clinical- grade generation of active-NK cells from cord blood hematopoietic progenitor-cells for immunotherapy using a closed- system culture-process. PLoS One. 2011;6(6):e20740. doi:10.1371/journal.pone.0020740
   PubMed Web of Science ®Google Scholar
• Knorr DA, Ni Z, Hermanson D, et al. Clinical- scale derivation of natural-killer cells from human pluripotent stem cells for-cancer therapy. Stem Cells Transl Med. 2013;2:274–283. doi:10.5966/sctm.2012-0084
   PubMed Web of Science ®Google Scholar
• Luevano M, Daryouzeh M, Alnabhan R, et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012;73(3):248–257. doi:10.1016/j.humimm.2011.12.015
   PubMed Web of Science ®Google Scholar
• Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol. 2005;175(8):5095–5103. doi:10.4049/jimmunol.175.8.5095
   Web of Science ®Google Scholar
• Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473–488. doi:10.1016/j.ccell.2020.07.005
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al.; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T- cell therapy in refractory large B- cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385. doi:10.1038/s41571-019-0184-6
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. Br J Haematol. 2009;145(5):606–613. doi:10.1111/j.1365-2141.2009.07667.x
   PubMed Web of Science ®Google Scholar
• Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane- bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7(1):e30264. doi:10.1371/journal.pone.0030264
   PubMed Web of Science ®Google Scholar
• Ojo EO, Sharma AA, Liu R, et al. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells. Sci Rep. 2019;9(1):14916. doi:10.1038/s41598-019-51287-6
   PubMed Web of Science ®Google Scholar
• Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. 2015;6:266. doi:10.3389/fimmu.2015.00266
   PubMed Web of Science ®Google Scholar
• Park HR, Ahn YO, Kim TM, et al. NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. Cytotherapy. 2019;21(6):603–611. doi:10.1016/j.jcyt.2019.03.312
   Web of Science ®Google Scholar
• Vallera DA, Felices M, McElmurry R, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res. 2016;22(14):3440–3450. doi:10.1158/1078-0432.CCR-15-2710
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014;8(2):297–310. doi:10.1016/j.molonc.2013.12.001
   PubMed Web of Science ®Google Scholar
• Nagashima S, Mailliard R, Kashii Y, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood. 1998;91(10):3850–3861. doi:10.1182/blood.V91.10.3850
   PubMed Web of Science ®Google Scholar
• Grote S, Mittelstaet J, Baden C, et al. Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. Oncoimmunology. 2020;9(1):1825177. doi:10.1080/2162402X.2020.1825177
   Web of Science ®Google Scholar
• Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 2020;472:175–180. doi:10.1016/j.canlet.2019.11.033
   PubMed Web of Science ®Google Scholar
• Marofi F, Rahman HS, Thangavelu L, et al. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res Ther. 2021;12(1):200. doi:10.1186/s13287-021-02251-7
   PubMed Web of Science ®Google Scholar
• Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. Front Immunol. 2020;11:167. doi:10.3389/fimmu.2020.00167
   PubMed Web of Science ®Google Scholar
• Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018;39(2):167–176. doi:10.1038/aps.2017.125
   PubMed Web of Science ®Google Scholar
• Tokarew N, Ogonek J, Endres S, von Bergwelt-baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26–37. doi:10.1038/s41416-018-0325-1
   PubMed Web of Science ®Google Scholar
• Molgora M, Cortez VS, Colonna M. Killing the invaders: NK cell impact in tumors and anti-tumor therapy. Cancers (Basel). 2021;13(4):595. doi:10.3390/cancers13040595
   Web of Science ®Google Scholar